530 related articles for article (PubMed ID: 9127315)
1. Transforming growth factor-alpha, epidermal growth factor receptor, and MiB-1 expression in Barrett's-associated neoplasia: correlation with prognosis.
Yacoub L; Goldman H; Odze RD
Mod Pathol; 1997 Feb; 10(2):105-12. PubMed ID: 9127315
[TBL] [Abstract][Full Text] [Related]
2. Loss or altered subcellular localization of p27 in Barrett's associated adenocarcinoma.
Singh SP; Lipman J; Goldman H; Ellis FH; Aizenman L; Cangi MG; Signoretti S; Chiaur DS; Pagano M; Loda M
Cancer Res; 1998 Apr; 58(8):1730-5. PubMed ID: 9563491
[TBL] [Abstract][Full Text] [Related]
3. Suppression of apoptosis does not foster neoplastic growth in Barrett's esophagus.
Soslow RA; Remotti H; Baergen RN; Altorki NK
Mod Pathol; 1999 Mar; 12(3):239-50. PubMed ID: 10102608
[TBL] [Abstract][Full Text] [Related]
4. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus.
O'Riordan JM; Abdel-latif MM; Ravi N; McNamara D; Byrne PJ; McDonald GS; Keeling PW; Kelleher D; Reynolds JV
Am J Gastroenterol; 2005 Jun; 100(6):1257-64. PubMed ID: 15929754
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of TGF-beta1 in esophageal (Barrett's) adenocarcinoma is associated with advanced stage of disease and poor prognosis.
von Rahden BH; Stein HJ; Feith M; Pühringer F; Theisen J; Siewert JR; Sarbia M
Mol Carcinog; 2006 Oct; 45(10):786-94. PubMed ID: 16921482
[TBL] [Abstract][Full Text] [Related]
6. Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome.
Wang KL; Wu TT; Choi IS; Wang H; Resetkova E; Correa AM; Hofstetter WL; Swisher SG; Ajani JA; Rashid A; Albarracin CT
Cancer; 2007 Feb; 109(4):658-67. PubMed ID: 17211865
[TBL] [Abstract][Full Text] [Related]
7. Expression of epidermal growth factor receptor, transforming growth factor-alpha and Ki-67 in relationship to malignant transformation of pleomorphic adenoma.
Katori H; Nozawa A; Tsukuda M
Acta Otolaryngol; 2007 Nov; 127(11):1207-13. PubMed ID: 17851915
[TBL] [Abstract][Full Text] [Related]
8. Clinical relevance of transforming growth factor alpha, epidermal growth factor receptor, p53, and Ki67 in colorectal liver metastases and corresponding primary tumors.
De Jong KP; Stellema R; Karrenbeld A; Koudstaal J; Gouw AS; Sluiter WJ; Peeters PM; Slooff MJ; De Vries EG
Hepatology; 1998 Oct; 28(4):971-9. PubMed ID: 9755233
[TBL] [Abstract][Full Text] [Related]
9. Gains and amplifications of c-myc, EGFR, and 20.q13 loci in the no dysplasia-dysplasia-adenocarcinoma sequence of Barrett's esophagus.
Rygiel AM; Milano F; Ten Kate FJ; Schaap A; Wang KK; Peppelenbosch MP; Bergman JJ; Krishnadath KK
Cancer Epidemiol Biomarkers Prev; 2008 Jun; 17(6):1380-5. PubMed ID: 18559552
[TBL] [Abstract][Full Text] [Related]
10. Ski/SnoN expression in the sequence metaplasia-dysplasia-adenocarcinoma of Barrett's esophagus.
Villanacci V; Bellone G; Battaglia E; Rossi E; Carbone A; Prati A; Verna C; Niola P; Morelli A; Grassini M; Bassotti G
Hum Pathol; 2008 Mar; 39(3):403-9. PubMed ID: 18261624
[TBL] [Abstract][Full Text] [Related]
11. Do angiogenesis and growth factor expression predict prognosis of esophageal cancer?
Millikan KW; Mall JW; Myers JA; Hollinger EF; Doolas A; Saclarides TJ
Am Surg; 2000 Apr; 66(4):401-5; discussion 405-6. PubMed ID: 10776879
[TBL] [Abstract][Full Text] [Related]
12. Apoptotic and proliferative activity in the neoplastic progression of Barrett's oesophagus: a comparative study.
Whittles CE; Biddlestone LR; Burton A; Barr H; Jankowski JA; Warner PJ; Shepherd NA
J Pathol; 1999 Apr; 187(5):535-40. PubMed ID: 10398118
[TBL] [Abstract][Full Text] [Related]
13. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus.
Bian YS; Osterheld MC; Bosman FT; Benhattar J; Fontolliet C
Mod Pathol; 2001 May; 14(5):397-403. PubMed ID: 11353048
[TBL] [Abstract][Full Text] [Related]
14. Increased expression of epidermal growth factor receptors in Barrett's esophagus associated with alkaline reflux: a putative model for carcinogenesis.
Jankowski J; Hopwood D; Pringle R; Wormsley KG
Am J Gastroenterol; 1993 Mar; 88(3):402-8. PubMed ID: 8438848
[TBL] [Abstract][Full Text] [Related]
15. Expression of beta-catenin, alpha-catenin, and E-cadherin in Barrett's esophagus and esophageal adenocarcinomas.
Washington K; Chiappori A; Hamilton K; Shyr Y; Blanke C; Johnson D; Sawyers J; Beauchamp D
Mod Pathol; 1998 Sep; 11(9):805-13. PubMed ID: 9758359
[TBL] [Abstract][Full Text] [Related]
16. Survivin, a potential biomarker in the development of Barrett's adenocarcinoma.
Vallböhmer D; Peters JH; Oh D; Kuramochi H; Shimizu D; Demeester SR; Hagen JA; Chandrasoma PT; Danenberg KD; DeMeester TR; Danenberg P
Surgery; 2005 Oct; 138(4):701-6; discussion 706-7. PubMed ID: 16269299
[TBL] [Abstract][Full Text] [Related]
17. Epidermal growth factor receptor expression in Barrett's esophagus.
Poller DN; Steele RJ; Morrell K
Arch Pathol Lab Med; 1992 Nov; 116(11):1226-7. PubMed ID: 1444753
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression.
Rusch V; Klimstra D; Venkatraman E; Pisters PW; Langenfeld J; Dmitrovsky E
Clin Cancer Res; 1997 Apr; 3(4):515-22. PubMed ID: 9815714
[TBL] [Abstract][Full Text] [Related]
19. Accumulation of p53 protein in normal, dysplastic, and neoplastic Barrett's oesophagus.
Krishnadath KK; Tilanus HW; van Blankenstein M; Bosman FT; Mulder AH
J Pathol; 1995 Feb; 175(2):175-80. PubMed ID: 7738712
[TBL] [Abstract][Full Text] [Related]
20. Pathologic prognostic factors in Barrett's associated adenocarcinoma: a follow-up study of 96 patients.
Torres C; Turner JR; Wang HH; Richards W; Sugarbaker D; Shahsafaei A; Odze RD
Cancer; 1999 Feb; 85(3):520-8. PubMed ID: 10091725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
